Skip to Content
U.S. National Institutes of Health
Last Updated: 11/28/13

Ovarian SPOREs

Ovarian cancer is the second most common gynecological cancer in women, but ranks first (above endometrial cancer) in cancer deaths. Approximately 22,240 new ovarian cancers will be diagnosed in the United States in 2013 and about 14,030 women will die from this disease. Recent large clinical studies of various chemotherapy regimens for OvCa showed little to no increase in progression free survival and no improvement in overall survival. Diagnosis is difficult due to an overall lack of early symptoms or screening methods for the disease. Thus patients present at advanced tumor stage with aggressive OvCa and vigorous tumor-induced immune suppression. Most patients who respond to surgery and chemotherapy relapse. Women with a family history of either breast, ovarian, or non-polyposis colon cancer are at an increased risk for developing ovarian cancer.

The Ovarian Cancer SPORE program was initiated in 1999 and in 2013 has five Ovarian SPOREs. Research areas cover a wide scope including early detection, imaging technologies, risk assessment, immunosuppression and novel therapeutic approaches. Translational projects explore cellular and molecular signaling pathways including DII4-Notch, MEK inhibition, PI3K and BRCA1/2, leading to personalized therapies. This includes developing additional therapies to reverse resistance to chemotherapy agents such as platinum. A expanding area of research is in harnessing the immune system for specific targeting of cancer cells including immunotherapy, vaccine therapy, oncolytic viruses, and enhancing tumor immunity. By collaborating the ovarian SPORE researchers share expertise, ideas and help with clinical accrual of patients.

Fred Hutchinson Cancer Research Center

Nicole Urban, ScD [Click Here]
Fred Hutchinson Cancer Research Center
Cancer Preventive Research Program
1100 Fairview Avenue North, M2-B230
PO Box 19024
Seattle, WA 98109
Tel: (206) 667-4677
Fax: (206) 667-7264
Email: nurban@fhcrc.org

For more information on this specific SPORE’s institution, please visit:
www.pocrc.org

Mayo Clinic, Rochester

Scott H. Kaufmann, M.D., PhD [Click Here]
Professor
Department of Pharmacology
Mayo Clinic Foundation
Guggenheim Room 1328
200 First St., Southwest
Rochester, MN 55905
Phone: (507) 284-8950
Fax: (507) 284-3906
Email: Kaufmann.Scott@Mayo.edu

For more information on this specific SPORE’s institution, please visit:
http://cancercenter.mayo.edu/mayo/research/womens_cancer/spore-ovarian.cfm

Research Institute of Fox Chase Cancer Center

Jeff Boyd, PhD
Professor and Chair
Research Institute of Fox Chase Cancer Center
333 Cottman Ave.
Philadelphia, PA 19111
Phone: (215) 728-2907
Fax: (215) 214-4053
Email: jeff.boyd@fccc.edu

For more information on this specific SPORE’s institution, please visit:
http://www.fccc.edu/cancer/types/gynecological/ovarian/spore.html

Roswell Park Cancer Institute

Kunle O. Odunsi, M.D., PhD [Click Here]
Professor
Gynecologic, Oncology & Immunology
Roswell Park Cancer Institute
Elm and Carltons Street
Buffalo, NY 14263
Phone: (716) 845-3497
Fax: (716) 845-7608
Email: kunle.odunsi@roswellpark.org

University of Texas/MD Anderson

Robert C. Bast, Jr., MD [Click Here]
University of Texas
M.D. Anderson Cancer Center
Department of Experimental Therapeutics
1515 Holcombe Boulevard, Unit 355
Houston, TX 77030
Tel: (713) 792-7743
Fax: (713) 792-7864
Email: rbast@mdanderson.org

For more information on this specific SPORE’s institution, please visit:
http://www.mdanderson.org/education-and-research/research-at-md-anderson/early-detection-and-treatment/research-programs/spores/ovarian-cancer-spore/index.html